Literature DB >> 11016663

Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells.

F Vacca1, A Bagnato, K J Catt, R Tecce.   

Abstract

Endothelin (ET)-1 is produced in ovarian carcinoma cells and is known to act through ET(A) receptors as an autocrine growth factor in vitro and in vivo. In OVCA 433 human ovarian carcinoma cells, ET-1 caused phosphorylation of the epidermal growth factor receptor (EGF-R) that was accompanied by phosphorylation of Shc and its recruitment complexed with Grb2. These findings suggested that an EGF-R/ras-dependent pathway may contribute to the activation of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (Erk) 2 and mitogenic signaling induced by ET-1 in these cells. Specific inhibition of EGF-R kinase activity by tyrphostin AG1478 prevented ET-1-induced transactivation of the EGF-R, as well as Shc phosphorylation and recruitment with Grb2. Furthermore, ET-1-induced activation of Erk 2 was partially inhibited by tyrphostin AG1478. In accord with this finding, the mitogenic action of ET-1 in OVCA 433 cells was also significantly reduced by a concentration of tyrphostin AG1478 that abolished the growth response of EGF-stimulated cells. Inhibition of protein kinase C activity, which contributes to the proliferative action of ET-1 in OVCA 433 cells, had no effect on the activation of Erk 2 by ET-1, which suggests that this effect of protein kinase C does not involve ras-independent activation of Erk 2. Inhibition by wortmannin of PI3-kinase activity, which has been implicated in ET-1 and other G protein-coupled receptor (GPCR)-mediated signaling pathways, reduced Erk 2 activation by ET-1 but had no effect on ET-1-induced EGF-R and Shc phosphorylation. These findings indicate that ET-1-induced stimulation of Erk 2 phosphorylation, and mitogenic responses in OVCA 433 ovarian cancer cells are mediated in part by signaling pathways that are initiated by transactivation of the EGF-R.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11016663

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells.

Authors:  Terry W Moody; Irene Ramos-Alvarez; Paula Moreno; Samuel A Mantey; Lisa Ridnour; David Wink; Robert T Jensen
Journal:  Peptides       Date:  2017-01-31       Impact factor: 3.750

Review 2.  Endothelin B receptor, a new target in cancer immune therapy.

Authors:  Lana E Kandalaft; Andrea Facciabene; Ron J Buckanovich; George Coukos
Journal:  Clin Cancer Res       Date:  2009-06-30       Impact factor: 12.531

Review 3.  Inhibition of ENaC by endothelin-1.

Authors:  Andrey Sorokin; Alexander Staruschenko
Journal:  Vitam Horm       Date:  2015-03-06       Impact factor: 3.421

4.  Simvastatin stimulates production of the antiapoptotic protein Bcl-2 via endothelin-1 and NFATc3 in SH-SY5Y cells.

Authors:  Tammy A Butterick; Urule Igbavboa; Gunter P Eckert; Grace Y Sun; Gary A Weisman; Walter E Müller; W Gibson Wood
Journal:  Mol Neurobiol       Date:  2010-04-06       Impact factor: 5.590

5.  Identification of a novel role for endothelins within the oviduct.

Authors:  Myoungkun Jeoung; Sungeun Lee; Hee-Kyung Hawng; Yong-Pil Cheon; Youn Kyung Jeong; Myung Chan Gye; Marc Iglarz; Chemyong Ko; Phillip J Bridges
Journal:  Endocrinology       Date:  2010-03-31       Impact factor: 4.736

6.  Current and Futuristic Roadmap of Ovarian Cancer Management: An Overview.

Authors:  Orlandric Miree; Sanjeev Kumar Srivastava; Santanu Dasgupta; Seema Singh; Rodney Rocconi; Ajay Pratap Singh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  The endothelin system in Morris hepatoma-7777: an endothelin receptor antagonist inhibits growth in vitro and in vivo.

Authors:  Thiemo Pfab; Gisela Stoltenburg-Didinger; Christoph Trautner; Michael Godes; Christian Bauer; Berthold Hocher
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

8.  Multiple mechanisms are responsible for transactivation of the epidermal growth factor receptor in mammary epithelial cells.

Authors:  Karin D Rodland; Nikki Bollinger; Danielle Ippolito; Lee K Opresko; Robert J Coffey; Richard Zangar; H Steven Wiley
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

Review 9.  Activated epidermal growth factor receptor in ovarian cancer.

Authors:  Laurie G Hudson; Reema Zeineldin; Melina Silberberg; M Sharon Stack
Journal:  Cancer Treat Res       Date:  2009

10.  Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

Authors:  Doris R Siwak; Mark Carey; Bryan T Hennessy; Catherine T Nguyen; Mollianne J McGahren Murray; Laura Nolden; Gordon B Mills
Journal:  J Oncol       Date:  2009-11-19       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.